Insulin sensitization by a novel partial peroxisome proliferator-activated receptor γ agonist with protein tyrosine phosphatase 1B inhibitory activity in experimental osteoporotic rats

Journal of Pharmacological Sciences

Volumn 124, Issue 2, 2014, Pages 276-285

  Kubo, Masahiro ^a,b   Fukui, Masaki ^a   Ito, Yuma ^a   Kitao, Tatsuya ^a   Shirahase, Hiroaki ^a   Hinoi, Eiichi ^b   Yoneda, Yukio ^b  

^a Research Laboratories   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Anti hyperlipidemia; Diabetes; Postmenopausal osteoporosis; Proliferator activated receptor (PPAR) ; Protein tyrosine phosphatase 1B (PTP1B)

Indexed keywords

7 [2 [2 (2 CYCLOPENTYLVINYL) 5 METHYLOXAZOL 4 YL]ETHOXY] 2 [(2,4) HEXADIENOYL] 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLIC ACID; ALKALINE PHOSPHATASE; FATTY ACID; INSULIN RECEPTOR; KY 201; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN TYROSINE PHOSPHATASE 1B; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VOLUME; BONE DENSITY; BONE MARROW; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; EXPERIMENTAL OSTEOPOROSIS; FAT IN MARROW; FEMALE; GROWTH INHIBITION; HEART WEIGHT; HIGH RISK POPULATION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; HYPOLIPIDEMIC ACTVITY; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIZATION; MEDICAL PARAMETERS; MESENCHYMAL STEM CELL; NONHUMAN; OBESITY; OSTEOBLAST; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRANSACTIVATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOCYTES; ANIMALS; BONE DENSITY; CELL DIFFERENTIATION; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; ISOQUINOLINES; OSTEOBLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; OXAZOLES; PPAR GAMMA; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RATS; RATS, INBRED F344; RECEPTOR, INSULIN; RISK; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 84895514997     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13236FP     Document Type: Article

References (34)

1. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88: 1254-1264.
2. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355: 2427-2443.
3. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2008;93: 703-716.
4. Schnabel CA, Wintle M, Kolterman O. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag. 2006;2: 69-77.
5. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22: 925-927.
6. Renda F, Mura P, Finco G, Ferrazin F, Pani L, Landoni G. Metformin-associated lactic acidosis requiring hospitalization. A national year survey and a systematic literature review. Eur Rev Med Pharmacol Sci. 2013;Suppl 1: 45-49.
7. Krische D. The glitazones: proceed with caution. West J Med. 2000;173: 54-57.
8. Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010;8: 178-184.
9. Cho N, Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem. 2008;8: 1483-1507.
10. Otake K, Azukizawa S, Fukui M, Shibabayashi M, Kamemoto H, Miike T, et al. A novel series of (S)-2, 7-substituted-1, 2, 3, 4-tetrahydroisoquinoline-3- carboxylic acids: peroxisome proliferator-activated receptor a/g dual agonists with protein-tyrosine phosphatase 1B inhibitory activity. Chem Pharm Bull. 2011;59: 1233-1242.
11. Cheng A, Dubé N, Gu F, Tremblay ML. Coordinated action of protein tyrosine phosphatases in insulin signal transduction. Eur J Biochem. 2002;269: 1050-1059.
12. Lund IK, Hansen JA, Andersen HS, Møller NP, Billestrup N. Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling. J Mol Endocrinol. 2005;34: 339-351.
13. Picardi PK, Calegari VC, Prada PO, Moraes JC, Araújo E, Marcondes MC, et al. Reduction of hypothalamic protein tyrosine phosphatase improves insulin and leptin resistance in diet-induced obese rats. Endocrinology. 2008;149: 3870-3880.
14. Fukuda S, Ohta T, Sakata S, Morinaga H, Ito M, Nakagawa Y, et al. Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551. Diabetes Obes Metab. 2010;12: 299-306.
15. Ma B, Zhang Q, Wang GJ, A JY, Wu D, Liu Y, et al. GC-TOF/MS-based metabolomic profiling of estrogen deficiency-induced obesity in ovariectomized rats. Acta Pharmacol Sin. 2011;32: 270-278.
16. Shrestha S, Bhattarai BR, Cho H, Choi JK, Cho H. PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta). Bioorg Med Chem Lett. 2007;17: 2728-2730.
17. Li M, Healy DR, Li Y, Simmons HA, Gao F, Ke HZ, et al. A comparison of the anabolic effects of rat and bovine parathyroid hormone (1-34) in ovariectomized rats. J Musculoskelet Neuronal Interact. 2001;2: 77-83.
18. Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia. 1997;40: 454-462.
19. Goldberg IJ, Eckel RH, Abumrad NA. Regulation of fatty acid uptake into tissues: lipoprotein lipase-and CD36-mediated pathways. J Lipid Res. 2009;50:S86-S90.
20. Yang B, Brown KK, Chen L, Carrick KM, Clifton LG, McNulty JA, et al. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol. 2004;4: 1-9.
21. Zabolotny JM, Haj FG, Kim YB, Kim HJ, Shulman GI, Kim JK, et al. Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem. 2004;279: 24844-24851.
22. Haj FG, Zabolotny JM, Kim YB, Kahn BB, Neel BG. Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice. J Biol Chem. 2005;280: 15038-15046.
23. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro et al. Mol Cell. 1999;4: 611-617.
24. Bełtowski J, Rachańczyk J, Włodarczyk M. Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms. PPAR Res. 2013;2013: 1-8.
25. Hasegawa H, Takano H, Komuro I. Therapeutic implications of PPARgamma in cardiovascular diseases. PPAR Res. 2010;2010: 1-12.
26. Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 2007;117: 2791-2801.
27. Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005;289:E735-E745.
28. Wan Y. PPARg in bone homeostasis. Trends Endocrinol Metab. 2010;21: 722-728.
29. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004;145: 401-406.
30. Ding J, Woo JT, Nagai K. The effects of retinoic acid on reversing the adipocyte differentiation into an osteoblastic tendency in ST2 cells, a murine bone marrow-derived stromal cell line. Cytotechnology. 2001;36: 125-136.
31. Takada I, Yogiashi Y, Kato S. Signaling Crosstalk between PPARg and BMP2 in Mesenchymal Stem Cells. PPAR Res. 2012;2012: 1-7.
32. Goto T, Nagai H, Egawa K, Kim YI, Kato S, Taimatsu A, et al. Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARg agonist. Biochem J. 2011;38: 111-119.
33. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care. 2005;28: 1419-1424.
34. Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, Gavrilova O, et al. WY14, 643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem. 2002;277: 24484-24489.